Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sepracor has initiated a phase I tolerability and pharmacokinetic study for its investigational drug SEP-225289 for the treatment of major depressive disorder.
Subscribe to our email newsletter
Based on preclinical study data, Sepracor believes that SEP-225289 has the potential to be a leading drug candidate in the newly emerging field of triple reuptake inhibitors (TUIs). SEP-225289 has been shown in preclinical studies to be a potent and balanced reuptake inhibitor of serotonin, norepinephrine and dopamine.
Serotonin, norepinephrine and dopamine are neurotransmitters associated with depression. There are currently no marketed treatments for depression that inhibit reuptake of all three neurotransmitters. Studies suggest that a triple mechanism of action may provide a broader spectrum of therapy than currently marketed antidepressants.
“We believe that a triple reuptake inhibitor may exhibit greater efficacy and faster onset of action than currently marketed antidepressants,” said Dr Mark Corrigan, executive vice president, R&D at Sepracor. “This novel combination of properties in a single compound… could have the potential to address a number of related maladies including substance abuse and other central nervous system conditions.”